C2CD5

Across TCGA pan-cancer cohorts, C2CD5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C2CD5 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher C2CD5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated C2CD5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SCLC, and BLCA are the cancer types where C2CD5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.923	0.614	.009	28	view →
SCLC	DFS	Median	III,IV	0.137	0.546	.042	6	view →
BLCA	OS	Median	IV	0.141	0.573	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C2CD5–UCEC (DFS)

Open the UCEC breakdown →